Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | November 10, 2023
Researchers sought to develop an NLP model to describe patients and tumor characteristics to more easily aggregate data.
Read More
David Ambinder, MDNon-Muscle Invasive Urothelial Carcinoma | October 30, 2023
Is there a better way to manage low-grade NMIBC? Adding UGN-102 to the current standard of care may be the answer.
Zachary BessetteESMO 2023 | October 27, 2023
Results of the phase 2b SunRISe-1 trial showed TAR-200 yields complete responses in BCG-unresponsive high-risk NMIBC.
Emily MenendezESMO 2023 | October 24, 2023
The TAR-210 delivery system provides a continuous release of erdafitinib to the bladder while limiting systemic toxicities.
Zachary BessetteESMO 2023 | October 23, 2023
An LBA shed light on the effects of erdafitinib in patients with high-risk NMIBC with select FGFR alterations after BCG.
Akhil Abraham Saji, MDRLT | October 5, 2023
This review highlights some of the most exciting abstracts and presentations in GU oncology at the ESMO Congress 2023.
Peter C. Black, MDNon-Muscle Invasive Urothelial Carcinoma | September 29, 2023
Dr. Black shares the basis for testing atezolizumab in BCG-unresponsive NMIBC as well as the implications of SWOG S1605.
Raj Satkunasivam, MD, MS, FRCSCNon-Muscle Invasive Urothelial Carcinoma | September 8, 2023
Dr. Satkunasivam shares the inspiration for combining sasanlimab with BCG in patients with high-risk, BCG-naïve NMIBC.
Sandip Prasad, MD, MPhilNon-Muscle Invasive Urothelial Carcinoma | August 30, 2023
Dr. Prasad provides overviews of ATLAS and ENVISION and opines on whether UGN-102 is a practice-ready alternative to TURBT.
Leah LawrenceNon-Muscle Invasive Urothelial Carcinoma | August 17, 2023
Several urologists weigh in on BCG, its role in NMIBC treatment, shortages, and strategies to treat BCG-unresponsive disease.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | August 8, 2023
The ATLAS study demonstrated the superiority of UGN-102 over TURBT for patients with low-grade, intermediate-risk NMIBC.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | August 4, 2023
UGN-102 is a sustained-release, hydrogel-based formula that allows bladder tissue to be exposed to mitomycin longer.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | July 10, 2023
Through molecular profiling, three different BCG response subtypes were found: BRS1, BRS2, and BRS3.
Emily MenendezASCO 2023 | June 1, 2023
An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | May 30, 2023
FDA approval of Adstiladrin for use in BCG-unresponsive NMIBC expands the armamentarium for treatment of high-risk NMIBC.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | May 1, 2023
NMIBC-associated costs vary widely across types of treatments utilized, health systems, and regions of the country.
Zachary BessetteAUA 2023: Focus on Bladder Cancer | April 29, 2023
There is significant inter-site variation in recurrence of NMIBC after TRUBT in the RESECT study, according to new research.
Emily MenendezAUA 2023: Focus on Bladder Cancer | April 28, 2023
Study results indicate an alternative strategy to radical cystectomy for comprehensive bladder-preserving therapy for MIBC.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | April 28, 2023
No nonsurgical treatments currently exist for patients with NMIBC who did not respond to BCG therapy.
Emily MenendezAUA 2023: Focus on Bladder Cancer | April 28, 2023
Patients with high-risk NMIBC who underwent TURBT from November 1993 to April 2019 were retrospectively evaluated.